Stemline Therapeutics, Inc.

Privately held: no public share price

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
Estrogen receptorSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 2
CD123Protein / enzyme therapeutic
Acute Myeloid Leukemia

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
ElacestrantPhase 2Metastatic Breast Cancer
Est. primary completion 2026-11 · NCT05596409 · CT.gov ↗
What to watch
December 2026 (1)
ElacestrantPhase 1/2Breast Cancer, Metastatic Breast Cancer
Est. primary completion 2026-12-27 · NCT05563220 · CT.gov ↗
What to watch
2027 (1)
August 2027 (1)
ElacestrantPhase 1/2Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases …
Est. primary completion 2027-08 · NCT05386108 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
TagraxofuspPhase 2Acute Myeloid Leukemia
Est. primary completion 2028-02-09 · NCT06456463 · CT.gov ↗
What to watch
October 2028 (1)
ElacestrantPhase 2Breast Cancer
Est. primary completion 2028-10 · NCT07766018 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
ElacestrantPhase 3Breast Cancer
Est. primary completion 2029-08 · NCT06492616 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.